GSK shares fall due to weaker vaccine sales and restructuring costs

• GSK reported better-than-expected financial results but saw its shares decline.
• Weaker sales of the shingles vaccine, particularly in China, contributed to the decline.
• Restructuring charges and an overall outlook unnerved investors.
• The company faces looming patent loss for its blockbuster HIV drug.
• Despite the decline, GSK remains Britain's second-biggest drugmaker.